Connecticut 2024 2024 Regular Session

Connecticut House Bill HB05235 Comm Sub / Bill

Filed 03/25/2024

                     
 
LCO    \\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-R01-
HB.docx  
1 of 30 
  
General Assembly  Substitute Bill No. 5235  
February Session, 2024 
 
 
 
 
 
AN ACT CONCERNING THE DEPARTMENT OF CONSUMER 
PROTECTION'S RECOMMENDATIONS REGARDING CANNABIS 
REGULATION.  
Be it enacted by the Senate and House of Representatives in General 
Assembly convened: 
 
Section 1. Section 21a-240 of the 2024 supplement to the general 1 
statutes is repealed and the following is substituted in lieu thereof 2 
(Effective from passage): 3 
The following words and phrases, as used in this chapter, shall have 4 
the following meanings, unless the context otherwise requires: 5 
(1) "Abuse of drugs" means the use of controlled substances solely for 6 
their stimulant, depressant or hallucinogenic effect upon the higher 7 
functions of the central nervous system and not as a therapeutic agent 8 
prescribed in the course of medical treatment or in a program of 9 
research operated under the direction of a physician or pharmacologist. 10 
(2) "Administer" means the direct application of a controlled 11 
substance, whether by injection, inhalation, ingestion or any other 12 
means, to the body of a patient or research subject by: (A) A practitioner, 13 
or, in the practitioner's presence, by the practitioner's authorized agent; 14 
[, or] (B) the patient or research subject at the direction and in the 15 
presence of the practitioner; [,] or (C) a nurse or intern under the 16  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
2 of 30 
 
direction and supervision of a practitioner. 17 
(3) "Agent" means an authorized person who acts on behalf of or at 18 
the direction of a manufacturer, distributor, dispenser or prescribing 19 
practitioner, but does not include a common or contract carrier, public 20 
warehouseman [,] or employee of the carrier or warehouseman. 21 
(4) "Amphetamine-type substances" include amphetamine, optical 22 
isomers thereof, salts of amphetamine and its isomers, and chemical 23 
compounds which are similar thereto in chemical structure or which are 24 
similar thereto in physiological effect, and which show a like potential 25 
for abuse, which are controlled substances under this chapter unless 26 
modified. 27 
(5) "Barbiturate-type drugs" include barbituric acid and its salts, 28 
derivatives thereof and chemical compounds which are similar thereto 29 
in chemical structure or which are similar thereto in physiological effect, 30 
and which show a like potential for abuse, which are controlled 31 
substances under this chapter unless modified. 32 
(6) "Bureau" means the Bureau of Narcotics and Dangerous Drugs, 33 
United States Department of Justice, or its successor agency. 34 
(7) "Cannabis-type substances" include all parts of any plant, or 35 
species of the genus cannabis or any infra specific taxon thereof whether 36 
growing or not; the seeds thereof; the resin extracted from any part of 37 
such a plant; and every compound, manufacture, salt, derivative, 38 
mixture or preparation of such plant, its seeds or resin; but shall not 39 
include the mature stalks of such plant, fiber produced from such stalks, 40 
oil or cake made from the seeds of such plant, any other compound, 41 
manufacture, salt, derivative, mixture or preparation of such mature 42 
stalks, except the resin extracted therefrom, fiber, oil or cake, the 43 
sterilized seed of such plant which is incapable of germination, or hemp, 44 
as defined in 7 USC 1639o, as amended from time to time. Included are 45 
cannabinon, cannabinol, cannabidiol and chemical compounds which 46 
are similar to cannabinon, cannabinol or cannabidiol in chemical 47  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
3 of 30 
 
structure or which are similar thereto in physiological effect, and which 48 
show a like potential for abuse, which are controlled substances under 49 
this chapter unless derived from hemp, as defined in section 22-61l. 50 
(8) "Controlled drugs" are those drugs which contain any quantity of 51 
a substance which has been designated as subject to the federal 52 
Controlled Substances Act, or which has been designated as a 53 
depressant or stimulant drug pursuant to federal food and drug laws, 54 
or which has been designated by the Commissioner of Consumer 55 
Protection pursuant to section 21a-243, as amended by this act, as 56 
having a stimulant, depressant or hallucinogenic effect upon the higher 57 
functions of the central nervous system and as having a tendency to 58 
promote abuse or psychological or physiological dependence, or both. 59 
Such controlled drugs are classifiable as amphetamine -type, 60 
barbiturate-type, cannabis-type, cocaine-type, hallucinogenic, 61 
morphine-type and other stimulant and depressant drugs. Specifically 62 
excluded from controlled drugs and controlled substances are alcohol, 63 
nicotine and caffeine. 64 
(9) "Controlled substance" means a drug, substance [,] or immediate 65 
precursor in schedules I to V, inclusive, of the Connecticut controlled 66 
substance scheduling regulations adopted pursuant to section 21a-243, 67 
as amended by this act. 68 
(10) "Counterfeit substance" means a controlled substance which, or 69 
the container or labeling of which, without authorization, bears the 70 
trademark, trade name or other identifying mark, imprint, number or 71 
device, or any likeness thereof, of a manufacturer, distributor or 72 
dispenser other than the person who in fact manufactured, distributed 73 
or dispensed the substance. 74 
(11) "Deliver or delivery" means the actual, constructive or attempted 75 
transfer from one person to another of a controlled substance, whether 76 
or not there is an agency relationship. 77 
(12) "Dentist" means a person authorized by law to practice dentistry 78  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
4 of 30 
 
in this state. 79 
(13) "Dispense" means to deliver a controlled substance to an ultimate 80 
user or research subject by or pursuant to the lawful order of a 81 
practitioner, including the prescribing, administering, packaging, 82 
labeling or compounding necessary to prepare the substance for the 83 
delivery. 84 
(14) "Dispenser" means a practitioner who dispenses. 85 
(15) "Distribute" means to deliver other than by administering or 86 
dispensing a controlled substance. 87 
(16) "Distributor" means a person who distributes and includes a 88 
wholesaler who is a person supplying or distributing controlled drugs 89 
which the person personally has not produced or prepared to hospitals, 90 
clinics, practitioners, pharmacies, other wholesalers, manufacturers and 91 
federal, state and municipal agencies. 92 
(17) "Drug" means: (A) [substances] Substances recognized as drugs 93 
in the official United States Pharmacopoeia, official Homeopathic 94 
Pharmacopoeia of the United States, or official National Formulary, or 95 
any supplement to any of them; (B) substances intended for use in the 96 
diagnosis, cure, mitigation, treatment or prevention of disease in man 97 
or animals; (C) substances, other than food, intended to affect the 98 
structure or any function of the body of man or animals; and (D) 99 
substances intended for use as a component of any article specified in 100 
subparagraph (A), (B) or (C) of this subdivision. [It] "Drug" does not 101 
include devices or their components, parts or accessories. 102 
(18) "Drug dependence" means a psychoactive substance dependence 103 
on drugs as that condition is defined in the most recent edition of the 104 
"Diagnostic and Statistical Manual of Mental Disorders" of the American 105 
Psychiatric Association. 106 
(19) "Drug-dependent person" means a person who has a 107 
psychoactive substance dependence on drugs as that condition is 108  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
5 of 30 
 
defined in the most recent edition of the "Diagnostic and Statistical 109 
Manual of Mental Disorders" of the American Psychiatric Association. 110 
(20) (A) "Drug paraphernalia" means equipment, products and 111 
materials of any kind that are used, intended for use or designed for use 112 
in planting, propagating, cultivating, growing, harvesting, 113 
manufacturing, compounding, converting, producing, processing, 114 
preparing, testing, analyzing, packaging, repackaging, storing, 115 
containing or concealing, or ingesting, inhaling or otherwise 116 
introducing into the human body, any controlled substance contrary to 117 
the provisions of this chapter, including, but not limited to: (i) Kits 118 
intended for use or designed for use in planting, propagating, 119 
cultivating, growing or harvesting of any species of plant that is a 120 
controlled substance or from which a controlled substance can be 121 
derived; (ii) kits used, intended for use or designed for use in 122 
manufacturing, compounding, converting, producing, processing or 123 
preparing controlled substances; (iii) isomerization devices used or 124 
intended for use in increasing the potency of any species of plant that is 125 
a controlled substance; (iv) testing equipment used, intended for use or 126 
designed for use in identifying or analyzing the strength, effectiveness 127 
or purity of controlled substances; (v) dilutents and adulterants, 128 
including, but not limited to, quinine hydrochloride, mannitol, mannite, 129 
dextrose and lactose used, intended for use or designed for use in 130 
cutting controlled substances; (vi) separation gins and sifters used, 131 
intended for use or designed for use in removing twigs and seeds from, 132 
or in otherwise cleaning or refining, marijuana; (vii) capsules and other 133 
containers used, intended for use or designed for use in packaging small 134 
quantities of controlled substances; (viii) containers and other objects 135 
used, intended for use or designed for use in storing or concealing 136 
controlled substances; and (ix) objects used, intended for use or 137 
designed for use in ingesting, inhaling, or otherwise introducing 138 
marijuana, cocaine, hashish [,] or hashish oil into the human body, 139 
including, but not limited to, wooden, acrylic, glass, stone, plastic or 140 
ceramic pipes with screens, permanent screens, hashish heads or 141 
punctured metal bowls; water pipes; carburetion tubes and devices; 142  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
6 of 30 
 
smoking and carburetion masks; roach clips; miniature cocaine spoons 143 
and cocaine vials; chamber pipes; carburetor pipes; electric pipes; air-144 
driven pipes; chillums; bongs; ice pipes and chillers. "Drug 145 
paraphernalia" does not include a product used by a manufacturer 146 
licensed pursuant to this chapter for the activities permitted under the 147 
license or by an individual to test any substance prior to injection, 148 
inhalation or ingestion of the substance to prevent accidental overdose 149 
by injection, inhalation or ingestion of the substance, provided the 150 
licensed manufacturer or individual is not using the product to engage 151 
in the unlicensed manufacturing or distribution of controlled 152 
substances. As used in this subdivision, "roach clip" means an object 153 
used to hold burning material, including, but not limited to, a marijuana 154 
cigarette, that has become too small or too short to be held between the 155 
fingers. 156 
(B) "Factory" means any place used for the manufacturing, mixing, 157 
compounding, refining, processing, packaging, distributing, storing, 158 
keeping, holding, administering or assembling illegal substances 159 
contrary to the provisions of this chapter, or any building, rooms or 160 
location which contains equipment or paraphernalia used for this 161 
purpose. 162 
(21) "Federal Controlled Substances Act, 21 USC 801 et seq." means 163 
Public Law 91-513, the Comprehensive Drug Abuse Prevention and 164 
Control Act of 1970. 165 
(22) "Federal food and drug laws" means the federal Food, Drug and 166 
Cosmetic Act, as amended, Title 21 USC 301 et seq. 167 
(23) "Hallucinogenic substances" are psychodysleptic substances, 168 
other than cannabis-type substances, which assert a confusional or 169 
disorganizing effect upon mental processes or behavior and mimic 170 
acute psychotic disturbances. Exemplary of such drugs are mescaline, 171 
peyote, psilocyn and d-lysergic acid diethylamide, which are controlled 172 
substances under this chapter unless modified. 173  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
7 of 30 
 
(24) "Hospital", as used in sections 21a-243 to 21a-283, inclusive, as 174 
amended by this act, means an institution for the care and treatment of 175 
the sick and injured, approved by the Department of Public Health or 176 
the Department of Mental Health and Addiction Services as proper to 177 
be entrusted with the custody of controlled drugs and substances and 178 
professional use of controlled drugs and substances under the direction 179 
of a licensed practitioner. 180 
(25) "Intern" means a person who holds a degree of doctor of 181 
medicine or doctor of dental surgery or medicine and whose period of 182 
service has been recorded with the Department of Public Health and 183 
who has been accepted and is participating in training by a hospital or 184 
institution in this state. Doctors meeting the foregoing requirements and 185 
commonly designated as "residents" and "fellows" shall be regarded as 186 
interns for purposes of this chapter. 187 
(26) "Immediate precursor" means a substance which the 188 
Commissioner of Consumer Protection has found to be, and by 189 
regulation designates as being, the principal compound commonly used 190 
or produced primarily for use, and which is an immediate chemical 191 
intermediary used or likely to be used, in the manufacture of a 192 
controlled substance, the control of which is necessary to prevent, curtail 193 
or limit manufacture. 194 
(27) "Laboratory" means a laboratory approved by the Department of 195 
Consumer Protection as proper to be entrusted with the custody of 196 
controlled substances and the use of controlled substances for scientific 197 
and medical purposes and for purposes of instruction, research or 198 
analysis. 199 
(28) "Manufacture" means the production, preparation, cultivation, 200 
growing, propagation, compounding, conversion or processing of a 201 
controlled substance, either directly or indirectly by extraction from 202 
substances of natural origin, or independently by means of chemical 203 
synthesis, or by a combination of extraction and chemical synthesis, and 204 
includes any packaging or repackaging of the substance or labeling or 205  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
8 of 30 
 
relabeling of its container, except that this term does not include the 206 
preparation or compounding of a controlled substance by an individual 207 
for the individual's own use or the preparation, compounding, 208 
packaging or labeling of a controlled substance: (A) By a practitioner as 209 
an incident to the practitioner administering or dispensing of a 210 
controlled substance in the course of such practitioner's professional 211 
practice; [,] or (B) by a practitioner, or by the practitioner's authorized 212 
agent under such practitioner's supervision, for the purpose of, or as an 213 
incident to, research, teaching or chemical analysis and not for sale. 214 
(29) "Marijuana" means all parts of any plant, or species of the genus 215 
cannabis or any infra specific taxon thereof, whether growing or not; 216 
[the seeds thereof;] the resin extracted from any part of the plant; every 217 
compound, manufacture, salt, derivative, mixture [,] or preparation of 218 
such plant, or its [seeds or] resin; [,] any high-THC hemp product; 219 
manufactured cannabinoids; [, synthetic cannabinoids, except as 220 
provided in subparagraph (E) of this subdivision;] or cannabinon, 221 
cannabinol or cannabidiol and chemical compounds which are similar 222 
to cannabinon, cannabinol or cannabidiol in chemical structure or which 223 
are similar thereto in physiological effect, which are controlled 224 
substances under this chapter, except cannabidiol derived from hemp, 225 
as defined in section 22-61l, that is not a high-THC hemp product. 226 
"Marijuana" does not include: (A) The mature stalks of such plant, fiber 227 
produced from such stalks, oil or cake made from the seeds of such 228 
plant, any other compound, manufacture, salt, derivative, mixture or 229 
preparation of such mature stalks, except the resin extracted from such 230 
mature stalks or fiber, oil or cake; (B) the sterilized seed of such plant 231 
which is incapable of germination; (C) hemp, as defined in section 22-232 
61l, (i) with a total THC concentration of not more than three-tenths per 233 
cent on a dry-weight basis, and (ii) that is not a high-THC hemp product; 234 
or (D) any substance approved by the federal Food and Drug 235 
Administration or successor agency as a drug and reclassified in any 236 
schedule of controlled substances or unscheduled by the federal Drug 237 
Enforcement Administration or successor agency which is included in 238 
the same schedule designated by the federal Drug Enforcement 239  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
9 of 30 
 
Administration or successor agency. [; or (E) synthetic cannabinoids 240 
which are controlled substances that are designated by the 241 
Commissioner of Consumer Protection, by whatever official, common, 242 
usual, chemical or trade name designation, as controlled substances and 243 
are classified in the appropriate schedule in accordance with 244 
subsections (i) and (j) of section 21a-243.] 245 
(30) "Narcotic substance" means any of the following, whether 246 
produced directly or indirectly by extraction from a substance of 247 
vegetable origin, or independently by means of chemical synthesis, or 248 
by a combination of extraction and chemical synthesis: (A) Morphine-249 
type: (i) Opium or opiate, or any salt, compound, derivative, or 250 
preparation of opium or opiate which is similar to any such substance 251 
in chemical structure or which is similar to any such substance in 252 
physiological effect and which shows a like potential for abuse, which 253 
is a controlled substance under this chapter unless modified; (ii) any 254 
salt, compound, isomer, derivative, or preparation of any such 255 
substance which is chemically equivalent or identical to any substance 256 
referred to in clause (i) of this [subdivision] subparagraph, but not 257 
including the isoquinoline alkaloids of opium; (iii) opium poppy or 258 
poppy straw; or (iv) (I) fentanyl or any salt, compound, derivative or 259 
preparation of fentanyl which is similar to any such substance in 260 
chemical structure or which is similar to any such substance in 261 
physiological effect and which shows a like potential for abuse, which 262 
is a controlled substance under this chapter unless modified, or (II) any 263 
salt, compound, isomer, derivative or preparation of any such substance 264 
which is chemically equivalent or identical to any substance referred to 265 
in subclause (I) of this clause; or (B) cocaine-type; coca leaves or any salt, 266 
compound, derivative or preparation of coca leaves, or any salt, 267 
compound, isomer, derivatives or preparation of any such substance 268 
which is chemically equivalent or identical to any such substance or 269 
which is similar to any such substance in physiological effect and which 270 
shows a like potential for abuse, but not including decocainized coca 271 
leaves or extractions of coca leaves which do not contain cocaine or 272 
ecgonine. 273  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
10 of 30 
 
(31) "Nurse" means a person performing nursing as defined in section 274 
20-87a. 275 
(32) "Official written order" means an order for controlled substances 276 
written on a form provided by the bureau for that purpose under the 277 
federal Controlled Substances Act. 278 
(33) "Opiate" means any substance having an addiction-forming or 279 
addiction-sustaining liability similar to morphine or being capable of 280 
conversion into a drug having addiction-forming or addiction-281 
sustaining liability; it does not include, unless specifically designated as 282 
controlled under this chapter, the dextrorotatory isomer of 3-methoxy-283 
n-methylmorthinan and its salts (dextro-methorphan) but shall include 284 
its racemic and levorotatory forms. 285 
(34) "Opium poppy" means the plant of the species papaver 286 
somniferum l., except its seed. 287 
(35) Repealed by P.A. 99-102, S. 51. 288 
(36) "Other stimulant and depressant drugs" means controlled 289 
substances other than amphetamine-type, barbiturate-type, cannabis-290 
type, cocaine-type, hallucinogenics and morphine-type which are found 291 
to exert a stimulant and depressant effect upon the higher functions of 292 
the central nervous system and which are found to have a potential for 293 
abuse and are controlled substances under this chapter. 294 
(37) "Person" includes any corporation, limited liability company, 295 
association or partnership, or one or more individuals, government or 296 
governmental subdivisions or agency, business trust, estate, trust, or 297 
any other legal entity. Words importing the plural number may include 298 
the singular; words importing the masculine gender may be applied to 299 
females. 300 
(38) "Pharmacist" means a person authorized by law to practice 301 
pharmacy pursuant to section 20-590, 20-591, 20-592 or 20-593. 302  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
11 of 30 
 
(39) "Pharmacy" means an establishment licensed pursuant to section 303 
20-594. 304 
(40) "Physician" means a person authorized by law to practice 305 
medicine in this state pursuant to section 20-9. 306 
(41) "Podiatrist" means a person authorized by law to practice 307 
podiatry in this state. 308 
(42) "Poppy straw" means all parts, except the seeds, of the opium 309 
poppy, after mowing. 310 
(43) "Practitioner" means: (A) A physician, dentist, veterinarian, 311 
podiatrist, scientific investigator or other person licensed, registered or 312 
otherwise permitted to distribute, dispense, conduct research with 313 
respect to or to administer a controlled substance in the course of 314 
professional practice or research in this state; and (B) a pharmacy, 315 
hospital or other institution licensed, registered or otherwise permitted 316 
to distribute, dispense, conduct research with respect to or to administer 317 
a controlled substance in the course of professional practice or research 318 
in this state. 319 
(44) "Prescribe" means order or designate a remedy or any 320 
preparation containing controlled substances. 321 
(45) "Prescription" means a written, oral or electronic order for any 322 
controlled substance or preparation from a licensed practitioner to a 323 
pharmacist for a patient. 324 
(46) "Production" includes the manufacture, planting, cultivation, 325 
growing or harvesting of a controlled substance. 326 
(47) "Registrant" means any person licensed by this state and 327 
assigned a current federal Bureau of Narcotics and Dangerous Drug 328 
Registry Number as provided under the federal Controlled Substances 329 
Act. 330  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
12 of 30 
 
(48) "Registry number" means the alphabetical or numerical 331 
designation of identification assigned to a person by the federal Drug 332 
Enforcement Administration, or other federal agency, which is 333 
commonly known as the federal registry number. 334 
(49) "Restricted drugs or substances" are the following substances 335 
without limitation and for all purposes: Datura stramonium; 336 
hyoscyamus niger; atropa belladonna, or the alkaloids atropine; 337 
hyoscyamine; belladonnine; apatropine; or any mixture of these 338 
alkaloids such as daturine, or the synthetic homatropine or any salts of 339 
these alkaloids, except that any drug or preparation containing any of 340 
the above-mentioned substances which is permitted by federal food and 341 
drug laws to be sold or dispensed without a prescription or written 342 
order shall not be a controlled substance; amyl nitrite; the following 343 
volatile substances to the extent that said chemical substances or 344 
compounds containing said chemical substances are sold, prescribed, 345 
dispensed, compounded, possessed or controlled or delivered or 346 
administered to another person with the purpose that said chemical 347 
substances shall be breathed, inhaled, sniffed or drunk to induce a 348 
stimulant, depressant or hallucinogenic effect upon the higher functions 349 
of the central nervous system: Acetone; benzene; butyl alcohol; butyl 350 
nitrate and its salts, isomers, esters, ethers or their salts; cyclohexanone; 351 
dichlorodifluoromethane; ether; ethyl acetate; formaldehyde; hexane; 352 
isopropanol; methanol; methyl cellosolve acetate; methyl ethyl ketone; 353 
methyl isobutyl ketone; nitrous oxide; pentochlorophenol; toluene; 354 
toluol; trichloroethane; trichloroethylene; 1,4 butanediol. 355 
(50) "Sale" is any form of delivery which includes barter, exchange or 356 
gift, or offer therefor, and each such transaction made by any person 357 
whether as principal, proprietor, agent, servant or employee. 358 
(51) "State", when applied to a part of the United States, includes any 359 
state, district, commonwealth, territory or insular possession thereof, 360 
and any area subject to the legal authority of the United States of 361 
America. 362  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
13 of 30 
 
(52) "State food, drug and cosmetic laws" means the Uniform Food, 363 
Drug and Cosmetic Act, section 21a-91 et seq. 364 
(53) "Ultimate user" means a person who lawfully possesses a 365 
controlled substance for the person's own use or for the use of a member 366 
of such person's household or for administering to an animal owned by 367 
such person or by a member of such person's household. 368 
(54) "Veterinarian" means a person authorized by law to practice 369 
veterinary medicine in this state. 370 
(55) "Wholesaler" means a distributor or a person who supplies 371 
controlled substances that the person personally has not produced or 372 
prepared to registrants. 373 
(56) "Reasonable times" means the time or times any office, care-374 
giving institution, pharmacy, clinic, wholesaler, manufacturer, 375 
laboratory, warehouse, establishment, store or place of business, vehicle 376 
or other place is open for the normal affairs or business or the practice 377 
activities usually conducted by the registrant. 378 
(57) "Unit dose drug distribution system" means a drug distribution 379 
system used in a hospital or chronic and convalescent nursing home in 380 
which drugs are supplied in individually labeled unit of use packages, 381 
each patient's supply of drugs is exchanged between the hospital 382 
pharmacy and the drug administration area or, in the case of a chronic 383 
and convalescent nursing home between a pharmacy and the drug 384 
administration area, at least once each twenty-four hours and each 385 
patient's medication supply for this period is stored within a patient-386 
specific container, all of which is conducted under the direction of a 387 
pharmacist licensed in Connecticut and, in the case of a hospital, directly 388 
involved in the provision and supervision of pharmaceutical services at 389 
such hospital at least thirty-five hours each week. 390 
(58) "Cocaine in a free-base form" means any substance which 391 
contains cocaine, or any compound, isomer, derivative or preparation 392 
thereof, in a nonsalt form. 393  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
14 of 30 
 
(59) "THC" means tetrahydrocannabinol, including, but not limited 394 
to, delta-7, delta-8-tetrahydrocannabinol, delta-9-tetrahydrocannabinol 395 
and delta-10-tetrahydrocannabinol, and any material, compound, 396 
mixture or preparation which contain their salts, isomers and salts of 397 
isomers, whenever the existence of such salts, isomers and salts of 398 
isomers is possible within the specific chemical designation, regardless 399 
of the source, except: (A) Dronabinol substituted in sesame oil and 400 
encapsulated in a soft gelatin capsule in a federal Food and Drug 401 
Administration or successor agency approved product; [,] or (B) any 402 
tetrahydrocannabinol product that has been approved by the federal 403 
Food and Drug Administration or successor agency to have a medical 404 
use and reclassified in any schedule of controlled substances or 405 
unscheduled by the federal Drug Enforcement Administration or 406 
successor agency. 407 
(60) "Total THC" means the sum of the percentage by weight of 408 
tetrahydrocannabinolic acid, multiplied by eight hundred seventy-409 
seven-thousandths, plus the percentage of weight of THC. 410 
(61) "Manufactured cannabinoid" means cannabinoids [naturally 411 
occurring from a source other than marijuana that are similar in 412 
chemical structure or physiological effect to cannabinoids derived from 413 
marijuana, as defined in section 21a-243, but are derived by a chemical 414 
or biological process] created by converting one cannabinoid directly to 415 
a different cannabinoid through: (A) Application of light or heat; (B) 416 
decarboxylation of naturally occurring acidic forms of cannabinoids; 417 
and (C) an alternate extraction or conversion process approved by the 418 
Department of Consumer Protection and published on the department's 419 
Internet web site. 420 
(62) "Synthetic cannabinoid": [means] (A) Means any [material, 421 
compound, mixture or preparation which contains any quantity of a 422 
substance having a psychotropic response primarily by agonist activity 423 
at cannabinoid-specific receptors affecting the central nervous system 424 
that is produced artificially and not derived from an organic source 425 
naturally containing cannabinoids, unless listed in another schedule 426  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
15 of 30 
 
pursuant to section 21a-243] substance converted by a chemical process 427 
to create a cannabinoid or cannabinoid-like substance that (i) has 428 
structural features which allow interaction with at least one of the 429 
known cannabinoid-specific receptors, or (ii) has any physiological or 430 
psychotropic response on at least one cannabinoid-specific receptor; and 431 
(B) excludes any cannabinoid that is (i) naturally produced, or (ii) 432 
manufactured through (I) application of light or heat, or (II) 433 
decarboxylation of naturally occurring acidic forms of cannabinoids. 434 
(63) "High-THC hemp product" means a manufacturer hemp 435 
product, as defined in section 22-61l, that has, or is advertised, labeled 436 
or offered for sale as having, total THC that exceeds: (A) [for] For a hemp 437 
edible, hemp topical or hemp transdermal patch (i) one milligram on a 438 
per-serving basis, or (ii) five milligrams on a per-container basis; [,] (B) 439 
for a hemp tincture, including, but not limited to, oil intended for 440 
ingestion by swallowing, buccal administration or sublingual 441 
absorption, (i) one milligram on a per-serving basis, or (ii) twenty-five 442 
milligrams on a per-container basis; [,] (C) for a hemp concentrate or 443 
extract, including, but not limited to, a vape oil, wax or shatter, twenty-444 
five milligrams on a per-container basis; [,] or (D) for a manufacturer 445 
hemp product not described in subparagraph (A), (B) or (C) of this 446 
subdivision, (i) one milligram on a per-serving basis, (ii) five milligrams 447 
on a per-container basis, or (iii) three-tenths per cent on a dry-weight 448 
basis for cannabis flower or cannabis trim. 449 
Sec. 2. Subsection (j) of section 21a-243 of the general statutes is 450 
repealed and the following is substituted in lieu thereof (Effective from 451 
passage): 452 
(j) Notwithstanding the provisions of subsection (c) of this section, 453 
the Commissioner of Consumer Protection shall designate the following 454 
substances, by whatever official, common, usual, chemical or trade 455 
name designation, as controlled substances in schedule I of the 456 
controlled substances scheduling regulations: 457 
(1) Mephedrone (4-methylmethcathinone); [and] 458  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
16 of 30 
 
(2) Synthetic cannabinoids; and 459 
[(2)] (3) MDPV (3,4-methyenedioxypyrovalerone). 460 
Sec. 3. Subparagraph (N) of subdivision (5) of subsection (b) of section 461 
21a-421j of the 2024 supplement to the general statutes is repealed and 462 
the following is substituted in lieu thereof (Effective from passage): 463 
(N) A requirement that, prior to being sold and transferred to a 464 
consumer, qualifying patient or caregiver, cannabis packaging be 465 
clearly labeled, whether printed directly on such packaging or affixed 466 
by way of a separate label, other than an extended content label, with: 467 
(i) A unique identifier generated by a cannabis analytic tracking 468 
system maintained by the department and used to track cannabis under 469 
the policies and procedures issued, and final regulations adopted, by 470 
the commissioner pursuant to this section; and 471 
(ii) The following information concerning the cannabis contained in 472 
such packaging, which shall be in legible English, black lettering, Times 473 
New Roman font, flat regular typeface, on a contrasting background 474 
and in uniform size of not less than one-tenth of one inch, based on a 475 
capital letter "K", which information shall also be available on the 476 
Internet web site of the cannabis establishment that sells and transfers 477 
such cannabis: 478 
(I) The name of such cannabis, as registered with the department 479 
under the policies and procedures issued, and final regulations adopted, 480 
by the commissioner pursuant to this section. 481 
(II) The expiration date, which shall not account for any refrigeration 482 
after such cannabis is sold and transferred to the consumer, qualifying 483 
patient or caregiver. 484 
(III) The net weight or volume, expressed in metric and imperial 485 
units. 486  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
17 of 30 
 
(IV) The standardized serving size, expressed in customary units, and 487 
the number of servings included in such packaging, if applicable. 488 
(V) Directions for use and storage. 489 
(VI) Each active ingredient comprising at least one per cent of such 490 
cannabis, including cannabinoids, isomers, esters, ethers and salts and 491 
salts of isomers, esters and ethers, and all quantities thereof expressed 492 
in metric units and as a percentage of volume. 493 
(VII) A list of all known allergens, as identified by the federal Food 494 
and Drug Administration, contained in such cannabis, or the denotation 495 
"no known FDA identified allergens" if such cannabis does not contain 496 
any allergen identified by the federal Food and Drug Administration. 497 
(VIII) The following warning statement within, and outlined by, a red 498 
box: 499 
"This product is not FDA-approved, may be intoxicating, cause long-500 
term physical and mental health problems, and have delayed side 501 
effects. It is illegal to operate a vehicle or machinery under the influence 502 
of cannabis. Keep away from children." 503 
(IX) At least one of the following warning statements, rotated 504 
quarterly on an alternating basis: 505 
"Warning: Frequent and prolonged use of cannabis can contribute to 506 
mental health problems over time, including anxiety, depression, 507 
stunted brain development and impaired memory." 508 
"Warning: Consumption while pregnant or breastfeeding may be 509 
harmful." 510 
"Warning: Cannabis has intoxicating effects and may be habit-511 
forming and addictive." 512 
"Warning: Consuming more than the recommended amount may 513 
result in adverse effects requiring medical attention.". 514  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
18 of 30 
 
(X) All information necessary to comply with labeling requirements 515 
imposed under the laws of this state [or] and federal law, including, but 516 
not limited to, sections 21a-91 to 21a-120, inclusive, and 21a-151 to 21a-517 
159, inclusive, the Federal Food, Drug and Cosmetic Act, 21 USC 301 et 518 
seq., as amended from time to time, and the federal Fair Packaging and 519 
Labeling Act, 15 USC 1451 et seq., as amended from time to time, for 520 
similar products that do not contain cannabis. 521 
(XI) Such additional warning labels for certain cannabis products as 522 
the commissioner may require and post on the department's Internet 523 
web site. 524 
Sec. 4. Section 21a-421aa of the general statutes is repealed and the 525 
following is substituted in lieu thereof (Effective from passage): 526 
(a) No cannabis retailer or hybrid retailer shall accept payment or 527 
other form of compensation directly or indirectly from a cultivator, 528 
micro-cultivator, producer, food and beverage manufacturer, product 529 
manufacturer or product packager to carry a cannabis product or for 530 
placement or promotion of such product in a retailer or hybrid retailer's 531 
establishment or through other promotional initiatives. No retailer or 532 
hybrid retailer shall enter into a contract with a cultivator, micro-533 
cultivator, producer, food and beverage manufacturer, product 534 
manufacturer or product packager that requires or permits preferential 535 
treatment, exclusivity or near exclusivity or limits a retailer or hybrid 536 
retailer from purchasing from other cultivators, micro-cultivators, 537 
producers, food and beverage manufacturers or product manufacturers 538 
in any way. 539 
(b) No cannabis establishment shall produce, manufacture or sell 540 
cannabis that is intended for use or consumption by animals. 541 
(c) A retailer or hybrid retailer shall not knowingly sell to a consumer 542 
more than one ounce of cannabis or the equivalent amount of cannabis 543 
products or combination of cannabis and cannabis products, as set forth 544 
in subsection (i) of section 21a-279a, per day, except that a hybrid retailer 545  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
19 of 30 
 
or dispensary facility may sell up to five ounces of cannabis or the 546 
equivalent amount of cannabis products or combination of cannabis and 547 
cannabis products to a qualifying patient or caregiver per day. 548 
Notwithstanding the requirements of sections 4-168 to 4-172, inclusive, 549 
to avoid cannabis supply shortages or address a public health and safety 550 
concern, the commissioner may set temporary lower per-transaction 551 
limits, which shall be published on the department's Internet web site. 552 
Such limits shall become ineffective upon the commissioner's 553 
determination that a supply shortage or public health and safety 554 
concern no longer exists. 555 
(d) No cannabis establishment, except a producer, cultivator or 556 
micro-cultivator, may acquire or possess a live cannabis plant. 557 
(e) No person issued a license or registration pursuant to RERACA 558 
shall (1) assign or transfer such license or registration without the 559 
commissioner's prior approval, or (2) sell, transfer or transport cannabis 560 
to, or obtain cannabis from, a location outside of this state if such activity 561 
would be in violation of federal law. 562 
(f) Synthetic cannabinoids, as defined in section 21a-240, as amended 563 
by this act, are prohibited in cannabis, and no synthetic cannabinoid 564 
may be sold at any cannabis establishment. 565 
Sec. 5. Subsection (a) of section 21a-421dd of the general statutes is 566 
repealed and the following is substituted in lieu thereof (Effective from 567 
passage): 568 
(a) No member of the Social Equity Council and no employee of the 569 
Social Equity Council or department who carries out the licensing, 570 
inspection, investigation, enforcement or policy decisions authorized by 571 
[RERACA] this chapter, and any regulations enacted pursuant thereto, 572 
may, directly or indirectly, have any management or financial interest 573 
in the cultivation, manufacture, sale, transportation, delivery or testing 574 
of cannabis in this state, nor receive any commission or profit from nor 575 
have any financial interest in purchases or sales made by [persons] 576  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
20 of 30 
 
cannabis establishments that are licensed pursuant to this chapter and 577 
authorized to make such purchases or sales pursuant to [RERACA] such 578 
license. No provision of this section shall prevent any such member or 579 
employee from purchasing and keeping in his or her possession, for his 580 
or her personal use or the use of such member's or employee's family or 581 
guests, any cannabis which may be purchased or kept by any person by 582 
virtue of [RERACA] this chapter. 583 
Sec. 6. Section 22-61m of the 2024 supplement to the general statutes 584 
is repealed and the following is substituted in lieu thereof (Effective from 585 
passage): 586 
(a) No person shall manufacture in the state without a license to 587 
manufacture issued by the Commissioner of Consumer Protection. 588 
(b) Each applicant for a manufacturer license shall submit an 589 
application on a form and in a manner prescribed by the Commissioner 590 
of Consumer Protection. 591 
(c) The following fees shall apply for a license to manufacture: 592 
(1) A nonrefundable license application fee of seventy-five dollars; 593 
and 594 
(2) A nonrefundable licensing fee of three hundred seventy-five 595 
dollars for a license to manufacture hemp. 596 
(d) A license to manufacture issued by the Commissioner of 597 
Consumer Protection pursuant to this section shall expire triennially on 598 
June thirtieth. Such licenses shall not be transferable. 599 
(e) In accordance with a hearing held pursuant to chapter 54, the 600 
Commissioner of Consumer Protection may deny, suspend or revoke a 601 
manufacturer license, issue fines of not more than two thousand five 602 
hundred dollars per violation and place conditions upon a 603 
manufacturer licensee who violates the provisions of this section and 604 
any regulation adopted pursuant to this section. 605  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
21 of 30 
 
(f) (1) Any individual who manufactures in this state without 606 
obtaining a license pursuant to this section or who manufactures in this 607 
state after such entity's license is suspended or revoked shall be fined 608 
two hundred fifty dollars in accordance with the provisions of section 609 
51-164n. 610 
(2) Any entity who manufactures in this state without obtaining a 611 
license pursuant to this section, or who manufactures in this state after 612 
having a license suspended, shall be fined not more than two thousand 613 
five hundred dollars per violation after a hearing conducted in 614 
accordance with the provisions of chapter 54. 615 
(g) Nothing in this chapter or any regulations adopted pursuant to 616 
this chapter shall be construed to apply to persons licensed pursuant to 617 
section 21a-408i nor to require persons licensed pursuant to said section 618 
to obtain a license pursuant to this chapter. 619 
(h) The Commissioner of Consumer Protection may inspect and shall 620 
have access to the buildings, equipment, supplies, vehicles, records, real 621 
property and other information of any manufacturer applicant or 622 
licensee that the commissioner deems necessary to carry out the 623 
commissioner's duties pursuant to this section. 624 
(i) (1) Each manufacturer shall follow the protocol in this subsection 625 
for disposing of cannabis in the event that any hemp or hemp product 626 
is deemed to exceed the prescribed THC concentration, as determined 627 
by the Commissioner of Consumer Protection, or a manufacturer 628 
licensee in possession of hemp or hemp products who desires to dispose 629 
of obsolete, misbranded, excess or otherwise undesired product. Each 630 
manufacturer licensee shall be responsible for all costs of disposal of 631 
hemp samples and any hemp produced by such licensee that violates 632 
the provisions of this section or any regulation adopted pursuant to this 633 
section. Any cannabis that exceeds the prescribed THC concentration 634 
allowable in hemp or hemp products shall be immediately embargoed 635 
by such manufacturer and clearly labeled as adulterated by such 636 
licensee and such licensee shall immediately notify both the Department 637  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
22 of 30 
 
of Consumer Protection and the Department of Agriculture, in writing, 638 
of such adulterated product. Such adulterated product shall be 639 
destroyed and disposed of by the following method, as determined by 640 
the Commissioner of Consumer Protection: 641 
(A) Surrender, without compensation, of such hemp or hemp product 642 
to the Commissioner of Consumer Protection who shall be responsible 643 
for the destruction and disposal of such adulterated product; or 644 
(B) By disposal in a manner prescribed by the Commissioner of 645 
Consumer Protection. 646 
(2) Notwithstanding the provisions of subdivision (1) of this 647 
subsection, upon written request of a manufacturer, the Commissioner 648 
of Consumer Protection may permit such manufacturer to combine 649 
different batches of raw hemp plant material to achieve a THC 650 
concentration of 0.3 per cent on a dry weight basis, in lieu of embargo 651 
or destruction. 652 
(j) The manufacturer or manufacturer's authorized designee 653 
disposing of the hemp or hemp products shall maintain and make 654 
available to the Commissioner of Consumer Protection a record of each 655 
such disposal or destruction of product indicating: 656 
(1) The date, time and location of disposal or destruction; 657 
(2) The manner of disposal or destruction; 658 
(3) The batch or lot information and quantity of hemp or hemp 659 
product disposed of or destroyed; and 660 
(4) The signatures of the persons disposing of the hemp or hemp 661 
products, the authorized representative of the Commissioner of 662 
Consumer Protection and any other persons present during the 663 
disposal. 664 
(k) Any hemp intended to be manufactured by a manufacturer into a 665  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
23 of 30 
 
manufacturer hemp product shall be tested by an independent testing 666 
laboratory located in this state. A manufacturer licensee shall make 667 
available samples, in an amount and type determined by the 668 
Commissioner of Consumer Protection, of hemp for an independent 669 
testing laboratory employee to select random samples. The independent 670 
testing laboratory shall test each sample in accordance with the 671 
laboratory testing standards established in policies, procedures and 672 
regulations adopted by the commissioner pursuant to section 21a-421j, 673 
as amended by this act. 674 
(l) Once a batch of hemp, intended to be sold as a manufacturer hemp 675 
product, has been homogenized for sample testing and eventual 676 
packaging and sale, until the independent testing laboratory provides 677 
the results from its tests and analysis, the manufacturer shall segregate 678 
and withhold from use the entire batch of hemp that is intended for use 679 
as a manufacturer hemp product, except the samples that have been 680 
removed by the independent testing laboratory for testing. During this 681 
period of segregation, the manufacturer licensee shall maintain the 682 
hemp batch in a secure, cool and dry location, as prescribed by the 683 
Commissioner of Consumer Protection, so as to prevent the hemp from 684 
becoming adulterated. Such manufacturer shall not manufacture or sell 685 
a manufacturer hemp product prior to the time that the independent 686 
testing laboratory completes testing and analysis and provides such 687 
results, in writing, to the manufacturer licensee who initiated such 688 
testing. 689 
(m) An independent testing laboratory shall immediately return or 690 
dispose of any hemp or manufacturer hemp product upon the 691 
completion of any testing, use or research. If an independent testing 692 
laboratory disposes of hemp or manufacturer hemp products, the 693 
laboratory shall dispose of such hemp in the following manner, as 694 
determined by the Commissioner of Consumer Protection: 695 
(1) By surrender, without compensation, of such hemp or 696 
manufacturer hemp product to the Commissioner of Consumer 697 
Protection who shall be responsible for the destruction and disposal of 698  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
24 of 30 
 
such hemp or hemp product; or 699 
(2) By disposal in a manner prescribed by the Commissioner of 700 
Consumer Protection. 701 
(n) If a sample does not pass the microbiological, mycotoxin, heavy 702 
metal or pesticide chemical residue test, based on the laboratory testing 703 
standards established in policies, procedures and regulations adopted 704 
by the Commissioner of Consumer Protection pursuant to section 21a-705 
421j, as amended by this act, the manufacturer licensee who sent such 706 
batch for testing shall: 707 
(1) Retest and reanalyze the hemp from which the sample was taken 708 
by having an employee from the same laboratory randomly select 709 
another sample from the same hemp batch. If the sample used to retest 710 
or reanalyze such hemp yields satisfactory results for all testing 711 
required under this section, an employee from a different laboratory 712 
shall randomly select a different sample from the same hemp batch for 713 
testing. If both samples yield satisfactory results for all testing required 714 
under this section, the hemp batch from which the samples were taken 715 
shall be released for manufacturing, processing and sale; 716 
(2) If a remediation plan sufficient to ensure public health and safety 717 
is submitted to and approved by the commissioner, remediate the hemp 718 
batch from which the sample was taken and have a laboratory employee 719 
randomly select a sample from such remediated hemp batch for testing. 720 
If such randomly selected sample yields satisfactory results for any 721 
testing required under this section, an employee from a different 722 
laboratory shall randomly select a different sample from the same hemp 723 
batch for testing. If both samples yield satisfactory results for all testing 724 
required under this section, the hemp batch from which the samples 725 
were taken may be released for manufacturing, processing or sale; or 726 
(3) If the manufacturer does not retest or remediate, or if any 727 
subsequent laboratory testing does not yield satisfactory results for any 728 
testing required under this section, dispose of the entire batch from 729  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
25 of 30 
 
which the sample was taken in accordance with procedures established 730 
by the Commissioner of Consumer Protection pursuant to subdivision 731 
(1) of subsection (i) of this section. 732 
(o) If a sample passes the microbiological, mycotoxin, heavy metal 733 
and pesticide chemical residue test, the independent testing laboratory 734 
shall release the entire batch for manufacturing, processing or sale. 735 
(p) The independent testing laboratory shall file with the Department 736 
of Consumer Protection an electronic copy of each laboratory test result 737 
for any batch that does not pass the microbiological, mycotoxin, heavy 738 
metal or pesticide chemical residue test, at the same time that it 739 
transmits such results to the manufacturer licensee who requested such 740 
testing. Each independent testing laboratory shall maintain the test 741 
results of each tested batch for a period of three years and shall make 742 
such results available to the Department of Consumer Protection upon 743 
request. 744 
(q) Manufacturers shall maintain records required by the federal act, 745 
this section, any regulation adopted pursuant to this section and the 746 
policies, procedures and regulations adopted by the Commissioner of 747 
Consumer Protection pursuant to section 21a-421j, as amended by this 748 
act. Each manufacturer shall make such records available to the 749 
Department of Consumer Protection immediately upon request and in 750 
electronic format, if available. 751 
(r) The Commissioner of Consumer Protection ma y adopt 752 
regulations, in accordance with the provisions of chapter 54, to 753 
implement the provisions of this section including, but not limited to, 754 
establishing sampling and testing procedures to ensure compliance 755 
with this section, prescribing storage and disposal procedures for hemp, 756 
marijuana and manufacturer hemp products that fail to pass 757 
Department of Consumer Protection prescribed independent testing 758 
laboratory testing standards and establishing advertising and labeling 759 
requirements for manufacturer hemp products. 760  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
26 of 30 
 
(s) Any claim of health impacts, medical effects or physical or mental 761 
benefits shall be prohibited on any advertising for, labeling of or 762 
marketing of manufacturer hemp products regardless of whether such 763 
manufacturer hemp products were manufactured in this state or 764 
another jurisdiction. Any violation of this subsection shall be deemed an 765 
unfair or deceptive trade practice under subsection (a) of section 42-766 
110b. 767 
(t) Not later than February 1, 2020, the Commissioners of Agriculture 768 
and Consumer Protection shall submit a report, in accordance with 769 
section 11-4a, to the joint standing committee of the general assembly 770 
having cognizance of matters relating to the environment on the status 771 
of the pilot program, the development of the state plan and any 772 
regulations for such pilot program or state plan. Such report shall also 773 
include any legislative recommendations, including, but not limited to, 774 
any recommendations for requiring the registration of any 775 
manufacturer hemp product offered for sale in this state. 776 
(u) (1) Any person who sells manufacturer hemp products shall not 777 
be required to be licensed, provided such person only engages in: (A) 778 
The retail or wholesale sale of manufacturer hemp products in which no 779 
further manufacturing of hemp occurs, provided such manufacturer 780 
hemp products are acquired from a person authorized to manufacture 781 
the manufacturer hemp products under the laws of this state or another 782 
state, territory or possession of the United States or another sovereign 783 
entity; (B) the acquisition of manufacturer hemp products for the sole 784 
purpose of product distribution for resale; and (C) the retail sale of 785 
manufacturer hemp products that is authorized under federal or state 786 
law. 787 
(2) The Commissioner of Consumer Protection or Commissioner of 788 
Revenue Services may, pursuant to section 4-182, summarily suspend 789 
any credential the Department of Consumer Protection or Department 790 
of Revenue Services issued to any person who sells manufacturer hemp 791 
products in violation of subdivision (1) of this subsection or subsections 792 
(v) to (y), inclusive, of this section. 793  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
27 of 30 
 
(v) No manufacturer hemp product offered for sale in this state, or to 794 
a consumer in this state, shall contain any synthetic cannabinoid, as 795 
defined in section 21a-240, as amended by this act. 796 
(w) No manufacturer hemp product offered for sale in this state, or 797 
to a consumer in this state, shall be packaged, presented or advertised 798 
in a manner that is likely to mislead a consumer by incorporating any 799 
statement, brand, design, representation, picture, illustration or other 800 
depiction that: (1) Bears a reasonable resemblance to trademarked or 801 
characteristic packaging of (A) cannabis offered for sale (i) in this state 802 
by a cannabis establishment licensed in this state, or (ii) on tribal land 803 
by a tribal-credentialed cannabis entity, or (B) a commercially available 804 
product other than a cannabis product, as defined in section 21a-420; or 805 
(2) implies that the manufacturer hemp product (A) is a cannabis 806 
product, as defined in section 21a-420, (B) contains a total THC 807 
concentration greater than three-tenths per cent on a dry-weight basis, 808 
or (C) is a high-THC hemp product, as defined in section 21a-240, as 809 
amended by this act. 810 
(x) No manufacturer hemp product that is a food, beverage, oil or 811 
other product intended for human ingestion shall be distributed or sold 812 
in this state unless such product is contained within a package, or a label 813 
is affixed to such package, that includes: 814 
(1) A scannable barcode, Internet web site address or quick response 815 
code that is linked to the certificate of analysis of the final form product 816 
batch by an independent testing laboratory and discloses: 817 
(A) The name of such product; 818 
(B) The name, address and telephone number of such product's 819 
manufacturer, packer and distributor, as applicable; 820 
(C) The batch number, which shall match the batch number on such 821 
package or label; and 822 
(D) The concentration of cannabinoids present in such product, 823  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
28 of 30 
 
including, but not limited to, total THC and any cannabinoids or active 824 
ingredients comprising at least one per cent of such product; 825 
(2) The expiration or best by date for such product, if applicable; 826 
(3) A clear and conspicuous statement disclosing that: 827 
(A) Children, or those who are pregnant or breastfeeding, should 828 
avoid using such product prior to consulting with a health care 829 
professional concerning such product's safety; 830 
(B) Products containing cannabinoids should be kept out of reach of 831 
children; and 832 
(C) The federal Food and Drug Administration has not evaluated 833 
such product for safety or efficacy; and 834 
(4) If such product is intended to be inhaled, a clear and conspicuous 835 
warning statement disclosing that smoking or vaporizing is hazardous 836 
to human health. 837 
(y) No manufacturer hemp product that is a topical, soap or cosmetic, 838 
as defined in section 21a-92, shall be distributed or sold in this state 839 
unless such product is contained within a package, or a label is affixed 840 
to such package, that includes: 841 
(1) A scannable barcode, Internet web site address or quick response 842 
code that is linked to the certificate of analysis of the final form extract 843 
or final form product batch by an independent testing laboratory and 844 
discloses: 845 
(A) The name of such product; 846 
(B) The name, address and telephone number of such product's 847 
manufacturer, packer and distributor, as applicable; 848 
(C) The batch number, which shall match the batch number on such 849 
package or label; and 850  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
29 of 30 
 
(D) The concentration of cannabinoids present in such batch, 851 
including, but not limited to, total THC and any marketed cannabinoids; 852 
(2) The expiration or best by date for such product, if applicable; and 853 
(3) A clear and conspicuous statement disclosing the following: 854 
"THE FDA HAS NOT EVALUATED THIS PRODUCT FOR SAFETY 855 
OR EFFICACY.". 856 
(z) Any violation of subsections (u) to (y), inclusive, of this section 857 
shall be deemed an unfair or deceptive trade practice under subsection 858 
(a) of section 42-110b. 859 
(aa) Not later than October 31, 2023, the Department of Emergency 860 
Services and Public Protection shall, in consultation with the 861 
Department of Consumer Protection, publish a training bulletin to 862 
inform local law enforcement agencies and officers regarding the 863 
investigation and enforcement standards concerning cannabis and high-864 
THC hemp products. 865 
(bb) Notwithstanding any provision of the general statutes: (1) CBD 866 
that is found in manufacturer hemp products shall not be considered a 867 
controlled substance, as defined in section 21a-240, as amended by this 868 
act, or legend drug, as defined in section 20-571; and (2) CBD derived 869 
from hemp and contained in manufacturer hemp products shall not be 870 
considered a controlled substance or adulterant. 871 
(cc) Nothing in this section shall be construed to prohibit shipment or 872 
transportation through this state of any hemp that is lawfully produced 873 
under federal law. 874 
This act shall take effect as follows and shall amend the following 
sections: 
 
Section 1 from passage 21a-240 
Sec. 2 from passage 21a-243(j) 
Sec. 3 from passage 21a-421j(b)(5)(N)  Substitute Bill No. 5235 
 
 
LCO    {\\PRDFS1\HCOUSERS\BARRYJN\WS\2024HB-05235-
R01-HB.docx }   
30 of 30 
 
Sec. 4 from passage 21a-421aa 
Sec. 5 from passage 21a-421dd(a) 
Sec. 6 from passage 22-61m 
 
GL Joint Favorable Subst.